The current consensus target is $5.8.
Advertisement
The stock price showcased downward shift from its 50 day moving average of 43.24 and stood below from its 200 Day Moving Average of 89.84. The company recorded the last trade with the price of $217.16. The 52-week high of the shares is $263.81 while the 52-week low is $25.27.
Citigroup (C) shares rose in early trading after the bank reported a beat on both its top and bottom lines for the first quarter. Capstone Asset Management Co. now owns 47,444 shares of the specialty pharmaceutical company’s stock worth $1,248,000 after buying an additional 6,047 shares during the last quarter.
In a different note, On Mar 21, 2016, Barclays said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. The company had a trading volume of 20,695,324 shares. The sales growth over the last 5 years is at 54.80% while earning per share for the last 12 months is at -0.77. Investors and analysts will be watching to see if the company will meet or beat the consensus EPS number of $0.05 for the quarter.
The next one year’s EPS estimate is set at $10.86 by 17 analysts while revenue forecast for the same year is $11.83B.
Several other research firms have also commented on VRX. Guggenheim reiterated a “buy” rating and issued a $195.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, December 17th. Given the historical price trends and product listings, Mizuho Analyst, Irina Koffler estimates $400 million as consideration for the non-core assets and suggests that her previous estimate of $1.7 billion might be a little too generous and definitely doesn’t provide any room for premium.
Bill Miller, chairman & CIO of LMM, said he’s optimistic about the future of Valeant Pharmaceuticals.
The Analyst Stock Recommendations are determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, Underperform or Sell.
Stock’s Ratings to Focus: Valeant Pharmaceuticals International, Inc. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Advertisement
While selling off an underperforming company’s various units to unlock value is an age-old tactic, it is unlikely to work unless those pieces are worth the sale.BMO Capital Markets analyst Alex Arfaei estimates that Valeant’s sum-of-parts may be equal to a stock price of $118 per share, representing a 267% premium over the company’s current share value.
